76 related articles for article (PubMed ID: 15358207)
1. GM-CSF cannot substitute for M-CSF in human osteoclastogenesis.
Hodge JM; Kirkland MA; Nicholson GC
Biochem Biophys Res Commun; 2004 Aug; 321(1):7-12. PubMed ID: 15358207
[TBL] [Abstract][Full Text] [Related]
2. Macrophage lineage phenotypes and osteoclastogenesis--complexity in the control by GM-CSF and TGF-beta.
Lari R; Fleetwood AJ; Kitchener PD; Cook AD; Pavasovic D; Hertzog PJ; Hamilton JA
Bone; 2007 Feb; 40(2):323-36. PubMed ID: 17055352
[TBL] [Abstract][Full Text] [Related]
3. Osteoclastic potential of human CFU-GM: biphasic effect of GM-CSF.
Hodge JM; Kirkland MA; Aitken CJ; Waugh CM; Myers DE; Lopez CM; Adams BE; Nicholson GC
J Bone Miner Res; 2004 Feb; 19(2):190-9. PubMed ID: 14969388
[TBL] [Abstract][Full Text] [Related]
4. Effect of vascular endothelial growth factor on RANK gene expression in osteoclast precursors and on osteoclastogenesis.
Yao S; Liu D; Pan F; Wise GE
Arch Oral Biol; 2006 Jul; 51(7):596-602. PubMed ID: 16443190
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of osteoprotegerin production in bone marrow macrophages by macrophage colony-stimulating factor.
Yamada N; Tsujimura T; Ueda H; Hayashi S; Ohyama H; Okamura H; Terada N
Cytokine; 2005 Aug; 31(4):288-97. PubMed ID: 15996478
[TBL] [Abstract][Full Text] [Related]
6. IL-6, LIF, and TNF-alpha regulation of GM-CSF inhibition of osteoclastogenesis in vitro.
Gorny G; Shaw A; Oursler MJ
Exp Cell Res; 2004 Mar; 294(1):149-58. PubMed ID: 14980510
[TBL] [Abstract][Full Text] [Related]
7. Macrophage colony-stimulating factor suppresses osteoblast formation.
Gyda M; Corisdeo S; Zaidi M; Troen BR
Biochem Biophys Res Commun; 2001 Jul; 285(2):328-34. PubMed ID: 11444846
[TBL] [Abstract][Full Text] [Related]
8. Multiple roles of M-CSF in human osteoclastogenesis.
Hodge JM; Kirkland MA; Nicholson GC
J Cell Biochem; 2007 Oct; 102(3):759-68. PubMed ID: 17516513
[TBL] [Abstract][Full Text] [Related]
9. Role of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis of bone marrow derived stem cells.
Bayoumy M; Sankar U; Muthusamy N
Indian J Exp Biol; 2002 Sep; 40(9):995-1000. PubMed ID: 12587726
[TBL] [Abstract][Full Text] [Related]
10. A signal through 4-1BB ligand inhibits receptor for activation of nuclear factor-kappaB ligand (RANKL)-induced osteoclastogenesis by increasing interferon (IFN)-beta production.
Shin HH; Lee EA; Kim SJ; Kwon BS; Choi HS
FEBS Lett; 2006 Mar; 580(6):1601-6. PubMed ID: 16480981
[TBL] [Abstract][Full Text] [Related]
11. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M
Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833
[TBL] [Abstract][Full Text] [Related]
12. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha.
Dai SM; Nishioka K; Yudoh K
Ann Rheum Dis; 2004 Nov; 63(11):1379-86. PubMed ID: 15479886
[TBL] [Abstract][Full Text] [Related]
13. Hepatocyte growth factor can substitute for M-CSF to support osteoclastogenesis.
Adamopoulos IE; Xia Z; Lau YS; Athanasou NA
Biochem Biophys Res Commun; 2006 Nov; 350(2):478-83. PubMed ID: 17022947
[TBL] [Abstract][Full Text] [Related]
14. Malignant B-lymphoid cells with bone lesions express receptor activator of nuclear factor-kappaB ligand and vascular endothelial growth factor to enhance osteoclastogenesis.
Shibata H; Abe M; Hiura K; Wilde J; Moriyama K; Sano T; Kitazoe K; Hashimoto T; Ozaki S; Wakatsuki S; Kido S; Inoue D; Matsumoto T
Clin Cancer Res; 2005 Sep; 11(17):6109-15. PubMed ID: 16144909
[TBL] [Abstract][Full Text] [Related]
15. The hematopoietic transcription factor PU.1 regulates RANK gene expression in myeloid progenitors.
Kwon OH; Lee CK; Lee YI; Paik SG; Lee HJ
Biochem Biophys Res Commun; 2005 Sep; 335(2):437-46. PubMed ID: 16083856
[TBL] [Abstract][Full Text] [Related]
16. CFU-GM-derived cells form osteoclasts at a very high efficiency.
Menaa C; Kurihara N; Roodman GD
Biochem Biophys Res Commun; 2000 Jan; 267(3):943-6. PubMed ID: 10673396
[TBL] [Abstract][Full Text] [Related]
17. Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts.
Chung YH; Chang EJ; Kim SJ; Kim HH; Kim HM; Lee SB; Ko JS
J Periodontal Res; 2006 Aug; 41(4):288-96. PubMed ID: 16827722
[TBL] [Abstract][Full Text] [Related]
18. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production.
Lee SK; Gardner AE; Kalinowski JF; Jastrzebski SL; Lorenzo JA
Bone; 2006 May; 38(5):678-85. PubMed ID: 16309985
[TBL] [Abstract][Full Text] [Related]
19. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.
Kubota T; Hoshino M; Aoki K; Ohya K; Komano Y; Nanki T; Miyasaka N; Umezawa K
Arthritis Res Ther; 2007; 9(5):R97. PubMed ID: 17892600
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
